Incidence, Predictors, and Impact on Survival of Left Ventricular Systolic Dysfunction and Recovery in Advanced Cancer Patients

5.00
Hdl Handle:
http://hdl.handle.net/10757/320254
Title:
Incidence, Predictors, and Impact on Survival of Left Ventricular Systolic Dysfunction and Recovery in Advanced Cancer Patients
Authors:
Oliveira, Guilherme H.; Mukerji, Siddarth; Hernández, Adrian V. ( 0000-0002-9999-4003 ) ; Qattan, Marwan Y.; Banchs, Jose; Durand, Jean-Bernard; Iliescu, Cezar; Plana, Juan Carlos; Tang, W.H. Wilson
Publisher:
Elsevier B.V.
Journal:
American Journal of Cardiology
Issue Date:
9-Jun-2014
URI:
http://hdl.handle.net/10757/320254
DOI:
10.1016/j.amjcard.2014.03.018
Additional Links:
http://www.sciencedirect.com/science/article/pii/S000291491400808X
Abstract:
Although left ventricular (LV) dysfunction occurs not uncommonly in the course of cancer therapy, little is known about its natural history and prognostic impact on patients. To investigate the incidence, predictors, and impact on survival of LV systolic dysfunction and recovery during cancer therapy, we conducted a retrospective cohort observational study over 1 year at the University of Texas MD Anderson Cancer Center. We enrolled patients with a decrease in ejection fraction by echocardiography to <50% while undergoing cancer therapy from January 2009 to December 2009.We collected and analyzed their chart data. Of 7,648 patients with echocardiograms in 2009, 366 (4.8%) had ejection fraction <50% and 104 met study criteria. LV systolic dysfunction was associated with cardiotoxic therapy in 53 patients (51%). Recovery occurred in 57 patients (55%) and was independently predicted by younger age, smaller left atrial volume index, and lower B-type natriuretic peptide. At last follow-up, 69 patients (66%) were dead, and 35 (34%) were alive. There was a 20% advantage in 2-year survival among patients with LV systolic recovery compared with those without (95% confidence interval 4% to 41%, p [ 0.02). In this retrospective study, LV systolic dysfunction recovery occurred in over half of the patients, appeared independent of cardiotoxic etiology, and associated with a 20% survival benefit at 2 years. Multivariable predictors of recovery are younger age, a small left atrial volume index, and lower B-type natriuretic peptide.
Type:
info:eu-repo/semantics/article
Rights:
info:eu-repo/semantics/openAccess
Language:
eng
ISSN:
0002-9149
EISSN:
1879-1913

Full metadata record

DC FieldValue Language
dc.contributor.authorOliveira, Guilherme H.spa
dc.contributor.authorMukerji, Siddarthspa
dc.contributor.authorHernández, Adrian V.spa
dc.contributor.authorQattan, Marwan Y.spa
dc.contributor.authorBanchs, Josespa
dc.contributor.authorDurand, Jean-Bernardspa
dc.contributor.authorIliescu, Cezarspa
dc.contributor.authorPlana, Juan Carlosspa
dc.contributor.authorTang, W.H. Wilsonspa
dc.date.accessioned2014-06-10T01:13:06Z-
dc.date.available2014-06-10T01:13:06Z-
dc.date.issued2014-06-09-
dc.identifier.issn0002-9149-
dc.identifier.doi10.1016/j.amjcard.2014.03.018-
dc.identifier.urihttp://hdl.handle.net/10757/320254-
dc.description.abstractAlthough left ventricular (LV) dysfunction occurs not uncommonly in the course of cancer therapy, little is known about its natural history and prognostic impact on patients. To investigate the incidence, predictors, and impact on survival of LV systolic dysfunction and recovery during cancer therapy, we conducted a retrospective cohort observational study over 1 year at the University of Texas MD Anderson Cancer Center. We enrolled patients with a decrease in ejection fraction by echocardiography to <50% while undergoing cancer therapy from January 2009 to December 2009.We collected and analyzed their chart data. Of 7,648 patients with echocardiograms in 2009, 366 (4.8%) had ejection fraction <50% and 104 met study criteria. LV systolic dysfunction was associated with cardiotoxic therapy in 53 patients (51%). Recovery occurred in 57 patients (55%) and was independently predicted by younger age, smaller left atrial volume index, and lower B-type natriuretic peptide. At last follow-up, 69 patients (66%) were dead, and 35 (34%) were alive. There was a 20% advantage in 2-year survival among patients with LV systolic recovery compared with those without (95% confidence interval 4% to 41%, p [ 0.02). In this retrospective study, LV systolic dysfunction recovery occurred in over half of the patients, appeared independent of cardiotoxic etiology, and associated with a 20% survival benefit at 2 years. Multivariable predictors of recovery are younger age, a small left atrial volume index, and lower B-type natriuretic peptide.spa
dc.formatapplication/pdfspa
dc.language.isoengeng
dc.publisherElsevier B.V.spa
dc.relation.urlhttp://www.sciencedirect.com/science/article/pii/S000291491400808Xspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.titleIncidence, Predictors, and Impact on Survival of Left Ventricular Systolic Dysfunction and Recovery in Advanced Cancer Patientsspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.identifier.eissn1879-1913-
dc.identifier.journalAmerican Journal of Cardiologyspa
dc.description.peer-reviewRevisión por paresspa
All Items in UPC are protected by copyright, with all rights reserved, unless otherwise indicated.